Michael Ulz

Clinical-stage biopharma Surface Oncology, Inc. (NASDAQ: SURF) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research.  The Analyst Analyst Michael Ulz initiated coverage of...

Mersana Therapeutics Inc (NASDAQ: MRSN) is closing out its first year as a public company, and in that time it’s cleared an investigational new drug application and earned endorsements from four Street analysts. Baird Equity Research expects the biotech will get even better with time. The...

NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat.  The Analyst Baird Equity Research's Michael Ulz...

The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with important data at the meeting. Here’s a look at some of the companies that Wall Street is...

Baird initiated coverage of Idera Pharmaceuticals Inc (NASDAQ: IDRA) with an Outperform rating and a $5 price target, suggesting 100-percent upside from current levels. Profiling the company, Baird said Idera is an emerging oncology and rare disease company, focusing on nucleic acid-based therapies...

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), a clinical-stage bio-pharmaceutical company, were trading higher by more than 7 percent Wednesday in reaction to an encouraging update regarding its Burosumab therapy which is used by patients with X-linked hypophosphatemia (XLH) in a Phase 3...

Baird has upgraded Amicus Therapeutics, Inc. (NASDAQ: FOLD) to Outperform, driven by the removal of two key overhangs in the form of regulatory clarity for Galafold in the United States and strengthening of the balance sheet. Further, the brokerage raised its target price by $3 to $10 on inclusion...

Baird believes Merrimack Pharmaceuticals Inc (NASDAQ: MACK) is taking steps in the right direction by announcing the sale of its metastatic pancreatic cancer drug Onivyde to French drug maker Ipsen and refocusing on its pipeline assets. The sale comes after Merrimack announcement in December to...